Huntington’s Disease (HD) is a genetic, neurodegenerative disorder that is characterised by motor, cognitive and neuropsychiatric dysfunction. We recently completed the HD-YAS study for which structural, diffusion, functional (resting state and task) and multiparametric mapping data were acquired in a group of young adults with the HD-gene.
The goal is to investigate the point at which brain changes begin to occur in HD gene-carriers; this is particularly important given the ongoing Phase 3 HD ‘gene silencing’ antisense oligonucleotide therapy trial and our understanding of the optimal time for therapeutic intervention.
- Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington’s disease. Psychological medicine, 1-7 DOI: 10.1017/s0033291720000094
- A small molecule kicks repeat expansion into reverse. Nature genetics, 52 (2), 136-137 DOI: 10.1038/s41588-020-0577-6
- View all publications by the Huntington’s Disease team